Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder.
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Mirabegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 28 Jan 2014 Results published in the BJU International.
- 18 Jun 2010 Primary endpoint 'Micturition rate' has been met according to an Astellas Pharma media release.
- 18 Jun 2010 A Market Authorisation Application for mirabegron has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan according to an Astellas Pharma media release. Results from this trial will be used in support of the application.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History